Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

From rapalogs to anti-aging formula.

Blagosklonny MV.

Oncotarget. 2017 May 30;8(22):35492-35507. doi: 10.18632/oncotarget.18033.

2.

Metformin Triggers Autophagy to Attenuate Drug-Induced Apoptosis in NSCLC Cells, with Minor Effects on Tumors of Diabetic Patients.

Xiao Z, Gaertner S, Morresi-Hauf A, Genzel R, Duell T, Ullrich A, Knyazev PG.

Neoplasia. 2017 May;19(5):385-395. doi: 10.1016/j.neo.2017.02.011. Epub 2017 Apr 7.

3.

AMP-activated protein kinase and energy balance in breast cancer.

Zhao H, Orhan YC, Zha X, Esencan E, Chatterton RT, Bulun SE.

Am J Transl Res. 2017 Feb 15;9(2):197-213. eCollection 2017. Review.

4.

Targeting Metabolic Remodeling in Triple Negative Breast Cancer in a Murine Model.

García-Castillo V, López-Urrutia E, Villanueva-Sánchez O, Ávila-Rodríguez MÁ, Zentella-Dehesa A, Cortés-González C, López-Camarillo C, Jacobo-Herrera NJ, Pérez-Plasencia C.

J Cancer. 2017 Jan 13;8(2):178-189. doi: 10.7150/jca.16387. eCollection 2017.

5.

Importance of CD200 expression by tumor or host cells to regulation of immunotherapy in a mouse breast cancer model.

Curry A, Khatri I, Kos O, Zhu F, Gorczynski R.

PLoS One. 2017 Feb 24;12(2):e0171586. doi: 10.1371/journal.pone.0171586. eCollection 2017.

6.

Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models.

Rico M, Baglioni M, Bondarenko M, Laluce NC, Rozados V, André N, Carré M, Scharovsky OG, Menacho Márquez M.

Oncotarget. 2017 Jan 10;8(2):2874-2889. doi: 10.18632/oncotarget.13760.

7.

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.

Cabello P, Pineda B, Tormo E, Lluch A, Eroles P.

Int J Mol Sci. 2016 Aug 10;17(8). pii: E1298. doi: 10.3390/ijms17081298.

8.

Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α-glucosidase inhibitor or a Nrf2-inducer.

Strong R, Miller RA, Antebi A, Astle CM, Bogue M, Denzel MS, Fernandez E, Flurkey K, Hamilton KL, Lamming DW, Javors MA, de Magalhães JP, Martinez PA, McCord JM, Miller BF, Müller M, Nelson JF, Ndukum J, Rainger GE, Richardson A, Sabatini DM, Salmon AB, Simpkins JW, Steegenga WT, Nadon NL, Harrison DE.

Aging Cell. 2016 Oct;15(5):872-84. doi: 10.1111/acel.12496. Epub 2016 Jun 16.

9.

Finding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging Molecules.

Kumar S, Lombard DB.

F1000Res. 2016 Mar 29;5. pii: F1000 Faculty Rev-406. doi: 10.12688/f1000research.7821.1. eCollection 2016. Review.

10.

Activation of autophagy flux by metformin downregulates cellular FLICE-like inhibitory protein and enhances TRAIL- induced apoptosis.

Nazim UM, Moon JH, Lee JH, Lee YJ, Seol JW, Eo SK, Lee JH, Park SY.

Oncotarget. 2016 Apr 26;7(17):23468-81. doi: 10.18632/oncotarget.8048.

11.

Repurposing old drugs to chemoprevention: the case of metformin.

Heckman-Stoddard BM, Gandini S, Puntoni M, Dunn BK, DeCensi A, Szabo E.

Semin Oncol. 2016 Feb;43(1):123-133. doi: 10.1053/j.seminoncol.2015.09.009. Epub 2015 Sep 8. Review.

12.

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders.

Evangelisti C, Cenni V, Lattanzi G.

Br J Clin Pharmacol. 2016 Nov;82(5):1229-1244. doi: 10.1111/bcp.12928. Epub 2016 May 18. Review.

13.

Energy disruptors: rising stars in anticancer therapy?

Bost F, Decoux-Poullot AG, Tanti JF, Clavel S.

Oncogenesis. 2016 Jan 18;5:e188. doi: 10.1038/oncsis.2015.46. Review.

14.

Metformin for cancer and aging prevention: is it a time to make the long story short?

Anisimov VN.

Oncotarget. 2015 Nov 24;6(37):39398-407. doi: 10.18632/oncotarget.6347.

15.

Metformin Treatment for the Prevention and/or Treatment of Breast/Mammary Tumorigenesis.

Grossmann ME, Yang DQ, Guo Z, Potter DA, Cleary MP.

Curr Pharmacol Rep. 2015 Apr 1;1(5):312-323.

16.

Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents.

Modica-Napolitano JS, Weissig V.

Int J Mol Sci. 2015 Jul 29;16(8):17394-421. doi: 10.3390/ijms160817394. Review.

17.

Targeting LKB1 in cancer - exposing and exploiting vulnerabilities.

Momcilovic M, Shackelford DB.

Br J Cancer. 2015 Aug 11;113(4):574-84. doi: 10.1038/bjc.2015.261. Epub 2015 Jul 21. Review.

18.

The effect of environmental chemicals on the tumor microenvironment.

Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan EP, Ryeom S, Salem HK, Scovassi AI, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH, Felsher DW.

Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.

19.

Metformin- A Promising Agent for Chemoprevention in BRCA1 Carriers.

Kumar NB, Vadaparampil ST, Mahajan N, Lilienfeld HS, Lee JH, Laronga C, Hakam A, Hein JJ, Egan KM, Arun B, Pal T.

Hereditary Genet. 2012 Jun;1(2). pii: 104. No abstract available.

20.

Increase in apoptosis by combination of metformin with silibinin in human colorectal cancer cells.

Tsai CC, Chuang TW, Chen LJ, Niu HS, Chung KM, Cheng JT, Lin KC.

World J Gastroenterol. 2015 Apr 14;21(14):4169-77. doi: 10.3748/wjg.v21.i14.4169.

Supplemental Content

Support Center